- Marbofloxacin
-
-
2026-06-04
- CAS:115550-35-1
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 500kgs
- Marbofloxacin
-
- $1.00
-
2026-06-03
- CAS:115550-35-1
- Min. Order: 1KG
- Purity: 99.0% ~ 101.0%
- Supply Ability: 50KG/month
- Marbofloxacin
-
- $35.00
-
2026-05-11
- CAS:115550-35-1
- Purity: 99.98%
- Supply Ability: 10g
|
| Product Name: | Marbofloxacin | | Synonyms: | 7h-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylicacid,2,3-dihydro-9-fluor;o-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-;MARBOFLOXACIN;Marbofloxacin, >=99%;9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-PIPERAZINO)-7-OXO-7H-PYRIDO[1,2,3-IJ][1,2,4]BENZOXADIAZINE-6-CARBOXYLIC ACID;ZENIQUIN(R);Marbofloxacin, Vetranal;7H-Pyrido3,2,1-ij4,1,2benzoxadiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo- | | CAS: | 115550-35-1 | | MF: | C17H19FN4O4 | | MW: | 362.36 | | EINECS: | 640-416-5 | | Product Categories: | API;Active Pharmaceutical Ingredients;Aromatics Compounds;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;115550-35-1 | | Mol File: | 115550-35-1.mol |  |
| | Marbofloxacin Chemical Properties |
| Melting point | 268-269°C (dec.) | | Boiling point | 571℃ | | density | 1.55±0.1 g/cm3(Predicted) | | Fp | >110°(230°F) | | storage temp. | Inert atmosphere,2-8°C | | solubility | Chloroform (Slightly, Heated) | | pka | 6.02±0.20(Predicted) | | form | Solid | | color | Light Yellow | | Water Solubility | Soluble in DMSO at 2mg/ml. Soluble in water or ethanol at <1mg/ml | | Merck | 14,5750 | | InChI | InChI=1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25) | | InChIKey | BPFYOAJNDMUVBL-UHFFFAOYSA-N | | SMILES | N12C=C(C(O)=O)C(=O)C3=C1C(=C(N1CCN(C)CC1)C(F)=C3)OCN2C | | CAS DataBase Reference | 115550-35-1(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 52/53-36/37/38 | | Safety Statements | 61-36-26-60 | | WGK Germany | 2 | | RTECS | UU8815140 | | HS Code | 29349990 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Aquatic Chronic 3 |
| | Marbofloxacin Usage And Synthesis |
| Brand Name(s) in US | Zeniquin, Marbocyl
| | Description | Marbofloxacin is a fluoroquinolone antibiotic that is active against P. multocida in vitro (MIC = 0.016 μg/ml). It exhibits broad-spectrum antibacterial activity mediated by the inhibition of DNA gyrase, with MIC values ranging from 0.016 to 0.4 and 0.19 to 1.7 μg/ml against various Gram-negative and Gram-positive bacterial isolates, respectively. In vivo, the administration of marbofloxacin (2 mg/kg, i.m.) after infection prevents the formation of pulmonary lesions in a bovine calf model of M. haemolytica A1 pneumonia. Oral marbofloxacin (2 mg/kg per day) also exhibits antileishmanial activity in a canine model of leishmaniasis, decreasing parasitic load by 72%. Formulations containing marbofloxacin have been used in the veterinary treatment of bacterial infections. | | Chemical Properties | Crystalline Solid | | Uses | A broad spectrum antibiotic commonly used to target Pseudomonas and Staphylococci species | | Uses | Fluorinated quinolone antibacterial | | Definition | ChEBI: A fluoroquinolone antibiotic that is 7-oxo-2,3-dihydro-7H-[1,3,4]oxadiazino[6,5,4-ij]quinoline substituted at positions 6, 9 and 10 by carboxy, fluoro and 4-methylpiperazin-1-yl groups, respectively. A synthetic, broad spect
um bactericidal agent, it is used in veterinary medicine, although its mechanism of action is not thoroughly understood. | | Application | Marbofloxacin is an FDA-approved broad-spectrum bactericidal fluoroquinolone available in oral tablet and injectable forms. It has been shown to have varying therapeutic effects in a wide range of animal diseases in dogs, cats, horses, cattle and pigs. It can be used to treat skin and soft tissue infections in dogs and cats, urinary tract infections in dogs, some blood borne pathogens (e.g. Mycoplasma haematobium) in cats, equine infections caused by susceptible bacteria, bovine respiratory disease, and porcine respiratory disease pathogens. | | Side effects | The most common side effects of Marbofloxacin are vomiting, diarrhoea and loss of appetite. More serious side effects include cartilage abnormalities (which may cause difficulty walking), prolonged loss of appetite, incoordination, convulsions, depression, fever, rash, or difficulty breathing. Blindness and eye damage in cats has been a concern at high doses. | | Veterinary Drugs and Treatments | Marbofloxacin is labeled for the treatment of susceptible bacterial
infections in dogs and cats. | | References | [1] AUDE A. FERRAN Alain B M Pierre Louis Toutain. Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection[J]. Veterinary microbiology, 2011, 148 2: Pages 292-297. DOI: 10.1016/j.vetmic.2010.09.005
[2] M. SPRENG. Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates[J]. Journal of veterinary pharmacology and therapeutics, 1995, 18 4: 284-289. DOI: 10.1111/j.1365-2885.1995.tb00592.x
[3] G. LHERMIE. Impact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica[J]. Frontiers in Microbiology, 2016, 7 1. DOI: 10.3389/fmicb.2016.00237
[4] CARMEN PINEDA. Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease.[J]. PLoS ONE, 2017: e0185981. DOI: 10.1371/journal.pone.0185981 |
| | Marbofloxacin Preparation Products And Raw materials |
|